Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 13, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 18, 2026
DirectorOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001140361-26-009900
Filed / recorded
Mar 18, 2026, 1:00 AM UTC
Added to OQRO
Oct 6, 2026, 9:54 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ADMA BIOLOGICS, INC.
Issuer CIK
1368514
Ticker
ADMA
Reporting person
Lawrence P. Guiheen
Relationship
Director
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Mar 13, 2026
Transaction code
M
Shares / units
30,000
Price per share
$3.66
Acquired / disposed
Acquired (A)
Shares owned after
135,520
Ownership form
Direct
Amendment
No
Footnotes from the filing
Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 94,830 shares of common stock owned by the Reporting Person.